{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:44Z","timestamp":1794587264224,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The objective of this investigation was to quantify the survival advantages by utilizing multi-center population-based data for delineating risk factors in female patients afflicted with lung adenocarcinoma (LUAD) bone metastases. Investigators analyzed surveillance, epidemiology, and end results data of 5534 female LUAD patients with bone metastases from 2010 to 2015, and subsequently split this cohort into a training set, an internal validation set, and an external cohort comprising a total of 114 patients. Independent risk factors screened by univariate and multivariate Cox analyses were used to create nomograms for overall survival in the training cohort, and the performance of the nomograms was assessed by calibration curves, receiver operating characteristic curves, and decision curve analysis curves. Kaplan\u2013Meier analyses were conducted to evaluate survival disparities based on patient risk stratification. Multivariate analysis unveiled that race, age, T stage, N stage, surgery, radiotherapy, chemotherapy, brain metastases, and liver metastases were independent prognostic factors. In the training set, the area under the curve values for 1-, 2-, and 3-year survival were 0.745, 0.728, and 0.727, respectively. The C-index attained values of 0.693, 0.681, and 0.744 across the 3 cohorts. Decision curve analysis indicates model may better inform clinical practice and decision-making than TNM staging. As evidenced by the Kaplan\u2013Meier survival curve, the high-risk cohort exhibited a marked and statistically significant reduction in survival rate compared to the low-risk cohort. We proficiently identified independent prognostic factors for overall survival among female LUAD patients. Furthermore, we formulated an innovative prognostic model capable of predicting 1-, 2-, and 3-year survival in this cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049353","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:27Z","timestamp":1782108027000},"page":"e49353","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Modeling survival prognosis in female patients with bone metastases from lung adenocarcinoma: A retrospective study based on the SEER database and a Chinese cohort"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5772-2124","authenticated-orcid":false,"given":"Zhi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, People\u2019s Hospital of Deyang City, Deyang, Sichuan, China"},{"name":"Department of Nuclear Medicine, Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University), Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, People\u2019s Hospital of Deyang City, Deyang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Third People\u2019s Hospital of Mianyang, Mianyang, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, People\u2019s Hospital of Deyang City, Deyang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","first-page":"17","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20261113","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer.","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"R4-20261113","first-page":"45","article-title":"Epidemiology of lung cancer.","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemp Oncol (Pozn)"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends.","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12890-024-02841-0","article-title":"Long-term trends of lung cancer incidence and survival in southeastern China, 2011-2020: a population-based study.","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Pulm Med"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R8-20261113","first-page":"79","article-title":"Lung cancer in women.","volume":"3","author":"Barrera-Rodriguez","year":"2012","journal-title":"Lung Cancer (Auckl)"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.3390\/ijerph19137618","article-title":"Characteristics of women with lung adenocarcinoma in the World Trade Center Environmental Health Center.","volume":"19","author":"Shum","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"600121","DOI":"10.3389\/fmed.2021.600121","article-title":"An overview of lung cancer in women and the impact of estrogen in lung carcinogenesis and lung cancer treatment.","volume":"8","author":"Rodriguez-Lara","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5306\/wjco.v5.i2.149","article-title":"Bone metastases: when and how lung cancer interacts with bone.","volume":"5","author":"Roato","year":"2014","journal-title":"World J Clin Oncol"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12885-021-08205-9","article-title":"Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from osimertinib treatment.","volume":"21","author":"Jarry","year":"2021","journal-title":"BMC Cancer"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12885-019-5534-3","article-title":"Clinical analysis of patients with skeletal metastasis of lung cancer.","volume":"19","author":"Cho","year":"2019","journal-title":"BMC Cancer"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases.","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"e005202","DOI":"10.1136\/bmjopen-2014-005202","article-title":"Risk factors for bone metastasis in patients with primary lung cancer: study protocol for a systematic review.","volume":"4","author":"Niu","year":"2014","journal-title":"BMJ Open"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis.","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer.","volume":"13","author":"Husemann","year":"2008","journal-title":"Cancer Cell"},{"key":"R18-20261113","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study.","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"e0234927","DOI":"10.1371\/journal.pone.0234927","article-title":"Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study.","volume":"15","author":"Hong","year":"2020","journal-title":"PLoS One"},{"key":"R20-20261113","doi-asserted-by":"crossref","first-page":"8970","DOI":"10.1038\/s41598-017-09650-y","article-title":"The risk factors of bone metastases in patients with lung cancer.","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2016.03.014","article-title":"The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases.","volume":"96","author":"Oliveira","year":"2016","journal-title":"Lung Cancer"},{"key":"R22-20261113","doi-asserted-by":"crossref","first-page":"9949714","DOI":"10.1155\/2021\/9949714","article-title":"Sites of synchronous distant metastases, prognosis, and nomogram for small cell lung cancer patients with bone metastasis: a large cohort retrospective study.","volume":"2021","author":"Fan","year":"2021","journal-title":"J Oncol"},{"key":"R23-20261113","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21037\/tlcr.2019.08.16","article-title":"Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study.","volume":"8","author":"Zheng","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R24-20261113","doi-asserted-by":"crossref","first-page":"1005668","DOI":"10.3389\/fonc.2022.1005668","article-title":"Development and validation of a prognostic nomogram for bone metastasis from lung cancer: a large population-based study.","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R25-20261113","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of survival in patients with bone metastasis of lung cancer.","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"R26-20261113","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.21037\/tcr-21-1507","article-title":"Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the Surveillance, Epidemiology and End Results (SEER) database.","volume":"10","author":"Shi","year":"2021","journal-title":"Transl Cancer Res"},{"key":"R27-20261113","doi-asserted-by":"crossref","first-page":"666332","DOI":"10.3389\/fsurg.2021.666332","article-title":"Outcome of non-small cell lung cancer patients with N3 stage: survival analysis of propensity score matching with a validated predictive nomogram.","volume":"8","author":"Han","year":"2021","journal-title":"Front Surg"},{"key":"R28-20261113","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer.","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"R29-20261113","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and interpreting decision curve analysis: a guide for investigators.","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur Urol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:00:42Z","timestamp":1794585642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":29,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049353","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2024-11-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}